



Press release from Emotra AB (publ)

Göteborg, June 8, 2021

Mangold Insight has published an updated analysis of Emotra and CEO Daniel Poté is interviewed by Mangold Insight

Emotra AB (“Emotra” or “the Company”) is proud to announce that Mangold Insight has published an updated analysis of the Company and that Emotra’s CEO Daniel Poté has been interviewed by Mangold Insight.

To read Mangold’s full press release (in Swedish), see [här](#).

To watch their interview with our CEO Daniel Poté (in Swedish), see [här](#).

To read Mangold Insight’s complete analysis (in Swedish), see [här](#).

Increased interest in Edor

Emotra is a medical-device company that has developed an instrument and a test method, EDOR® (“Electro Dermal Orienting Reactivity”), that identifies hyporeactive patients. Hyporeactive patients run a higher risk of suffering from depressions that are difficult to treat and depression relapse. Depression is a major problem in psychiatric care, with a lack of objective diagnostic markers that provide information that can be used to screen patients for higher or lower risk of depression relapse. The Company has collected data that supports the indication of hyporeactivity and which will facilitate our marketing efforts with hospitals and clinics. Improving diagnostics by testing patients with EDOR could lead to improved and safer health care, as well as enormous cost savings for society. The healthcare sector is a conservative industry and new innovations need to prove their effectiveness before they can gain acceptance.

Groundbreaking study

The results of our first study, which focused on depression relapse, have been published. This scientific article (Clinical effectiveness of the electrodermal orienting reactivity test for evaluating relapse and recurrence risk in patients hospitalized for depression) has been published in BMC Psychiatry. The study showed that depressed in-patients, and who EDOR tests indicate as hyporeactive, run a five times greater risk of depression relapse within ten months from being discharged.

Exciting collaboration with a Japanese company

Emotra is looking for collaboration partners for studies. We have signed an agreement with the Japanese company Beauty Life Corporation through which we together will investigate future opportunities for EDOR on the Japanese market. Beauty Life is active in the neuroscientific sector and works with Tokushima University in various areas. With this collaboration, Emotra has taken its first steps on the Japanese market.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.



Emotra AB, AstraZeneca BioVentureHub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se